[
  {
    "ts": null,
    "headline": "Biogen highlights ‘promising’ results for higher-dose nusinersen in SMA trials",
    "summary": "Biogen (BIIB) announced new data that it says reinforce the clinical impact of nusinersen across a broad spectrum of individuals affected by spinal muscular atrophy. These latest findings from Part C of the DEVOTE trial evaluating a higher dose regimen of nusinersen and the NURTURE trial which evaluated the approved 12 mg regimen — SPINRAZA — in clinically presymptomatic SMA were presented at the SMA Research & Clinical Care Meeting hosted by Cure SMA in Anaheim, Calif. Biogen’s applications for",
    "url": "https://finnhub.io/api/news?id=1750506322093600e8cc302d3c220d7c1b3877871c0499e2efe8d3ffe37e6f9b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751119510,
      "headline": "Biogen highlights ‘promising’ results for higher-dose nusinersen in SMA trials",
      "id": 135624029,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen (BIIB) announced new data that it says reinforce the clinical impact of nusinersen across a broad spectrum of individuals affected by spinal muscular atrophy. These latest findings from Part C of the DEVOTE trial evaluating a higher dose regimen of nusinersen and the NURTURE trial which evaluated the approved 12 mg regimen — SPINRAZA — in clinically presymptomatic SMA were presented at the SMA Research & Clinical Care Meeting hosted by Cure SMA in Anaheim, Calif. Biogen’s applications for",
      "url": "https://finnhub.io/api/news?id=1750506322093600e8cc302d3c220d7c1b3877871c0499e2efe8d3ffe37e6f9b"
    }
  },
  {
    "ts": null,
    "headline": "Biogen Advances Once-Yearly SMA Therapy Salanersen to Phase 3 After Positive Phase 1 Results",
    "summary": "Biogen Inc. (NASDAQ:BIIB) is one of the most undervalued US stocks according to analysts. On June 25, Biogen announced positive topline results from an interim analysis of its Phase 1 study for salanersen (BIIB115/ION306), which is an investigational antisense oligonucleotide/ASO for treating spinal muscular atrophy/SMA. Based on these encouraging findings, Biogen is engaging with global […]",
    "url": "https://finnhub.io/api/news?id=b4312990b1e53f7e6820b12d9eebefd419acdb918ad558314580b421c8ed6686",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751098594,
      "headline": "Biogen Advances Once-Yearly SMA Therapy Salanersen to Phase 3 After Positive Phase 1 Results",
      "id": 135624030,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen Inc. (NASDAQ:BIIB) is one of the most undervalued US stocks according to analysts. On June 25, Biogen announced positive topline results from an interim analysis of its Phase 1 study for salanersen (BIIB115/ION306), which is an investigational antisense oligonucleotide/ASO for treating spinal muscular atrophy/SMA. Based on these encouraging findings, Biogen is engaging with global […]",
      "url": "https://finnhub.io/api/news?id=b4312990b1e53f7e6820b12d9eebefd419acdb918ad558314580b421c8ed6686"
    }
  }
]